very nice news for ICGN
DJ Icagen Reports Results Of Data Monitoring Committee Meeting In Phase III Assert Trial Of ICA-17043>ICGN
09/12/2006
Dow Jones News Services
(Copyright © 2006 Dow Jones & Company, Inc.)
(MORE TO FOLLOW) Dow Jones Newswires
09-12-06 0730ET
Copyright (c) 2006 Dow Jones & Company, Inc.
*DJ Icagen: Committee Recommends Assert Trial Continue Enrollment
(MORE TO FOLLOW) Dow Jones Newswires
09-12-06 0734ET
Copyright (c) 2006 Dow Jones & Company, Inc.
DJ Icagen Cmte Urges Combination Therapy In Sickle-Cell Trial
DOW JONES NEWSWIRES
Icagen Inc. (ICGN) said its independent data-monitoring committee recommended continuing to enroll patients on a combination therapy in the company's Phase III clinical trial of an oral sickle-cell disease treatment.
The Durham, N.C., biopharmaceutical company said the data committee recommended continuing to enroll patients on hydroxyurea therapy in its clinical trial of ICA-17043 to treat the genetic blood disorder.
Icagen said combination therapy might prove more effective at treating the disease than a single treatment alone; the company said it would discuss the committee's recommendation with the U.S. Food and Drug Administration.
